4A3.F immatics biotechnologies GmbH
- Market cap
- EUR 861M
- P/E
- -
- P/B
- 2.03x
- ROE
- -59.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 4A3.F undervalued?
Graham numberThe Graham number of immatics biotechnologies GmbH cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
immatics biotechnologies GmbH fundamental analysis
No fundamental analysis for immatics biotechnologies GmbH yet.
immatics biotechnologies GmbH stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME c…
Full company profileimmatics biotechnologies GmbH financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
immatics biotechnologies GmbH annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 3.77M | 18.4M | 31.3M | 34.8M | 173M | 54.0M | 156M | 48.3M | 31.6M |
| Operating Income | -34.4M | -33.0M | -69.7M | -86.3M | 30.0M | -102M | -38.6M | -182M | -282M |
| EBITDA | -30.2M | -28.5M | -225M | -86.3M | 57.3M | -88.9M | 34.5M | -185M | -250M |
| Net Income | -31.4M | -31.6M | -229M | -93.3M | 37.5M | -94.6M | 15.2M | -196M | -262M |
| EPS | - | -0.50 | -3.64 | -1.48 | 0.49 | -1.12 | 0.13 | -1.47 | -1.72 |
| Balance Sheet | |||||||||
| Total Assets | - | 134M | 255M | 175M | 408M | 510M | 696M | 562M | 566M |
| Total Liabilities | - | 175M | 150M | 151M | 195M | 285M | 121M | 78.2M | 127M |
| Shareholders' Equity | - | -41.9M | 104M | 24.1M | 213M | 225M | 575M | 484M | 438M |
| Cash & Short-term Investments | - | 103M | 208M | 133M | 149M | 218M | 237M | 346M | 277M |
| Cash Flow | |||||||||
| Operating Cash Flow | 20.7M | 71.0M | 100M | 100M | 100M | 18.2M | -158M | -177M | -218M |
| Capital Expenditure | 429K | 2.14M | 7.42M | 5.11M | 5.74M | 31.0M | 16.5M | 6.81M | 3.25M |
| Free Cash Flow | 20.2M | 68.7M | -93.1M | -87.4M | 93.9M | -12.7M | -175M | -183M | -221M |
| Ratios | |||||||||
| ROE | - | - | -219.7% | -387.9% | 17.6% | -42.1% | 2.6% | -40.6% | -59.7% |
| ROA | - | -23.5% | -90.0% | -53.4% | 9.2% | -18.6% | 2.2% | -34.9% | -46.3% |
| Net Profit Margin | -834.1% | -171.1% | -732.9% | -268.5% | 21.7% | -175.3% | 9.8% | -407.0% | -829.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
immatics biotechnologies GmbH dividends
immatics biotechnologies GmbH has not paid dividends in the last 8 fiscal years.
Who owns immatics biotechnologies GmbH
- Insiders 15.93%
- Institutions 67.36%
- Public & others 16.72%
- Shares outstanding 152M
- Free float 78.0M
immatics biotechnologies GmbH company profile
- Company name
- immatics biotechnologies GmbH
- Ticker
- 4A3.F
- ISIN
- NL0015285941
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 589
- Fiscal year end
- December
- Address
- Paul-Ehrlich-Strasse 15-19, Tübingen, Germany, 72076
- Phone
- 49 7071 5397 0
- Website
- immatics.com
About immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
immatics biotechnologies GmbH management
10- Dr. Harpreet Singh Ph.D.CEO, MD, Member of Management Board & Executive Director · born 1975
- Dr. Venkat Ramanan Ph.D.Chief Financial Officer · born 1970
- Ms. Amie KrauseChief People Officer · born 1973
- Dr. Hans-Georg Rammensee Ph.D.Co-Founder & Member of the Scientific Advisory Board
- Dr. Toni Weinschenk Ph.D.Co-Founder & Chief Innovation Officer · born 1970
- Mr. Steffen Walter Ph.D.Chief Operations Officer · born 1977
- Mr. Ephraim Hofsäß M.Sc.Vice President of SEC Reporting & Accounting
- Mr. James Pepin J.D.General Counsel & Corporate Secretary
- Ms. Lauren SchroederVice President of Marketing
- Dr. Carsten Reinhardt M.D., Ph.D.Chief Development Officer · born 1967